Literature DB >> 3970058

Anaphylactic reaction and cardiopulmonary arrest following intravenous cyclosporine.

L S Friedman, J L Dienstag, P W Nelson, P S Russell, A B Cosimi.   

Abstract

Cyclosporine, a new immunosuppressive agent useful in recipients of a variety of organ transplants, has been associated with a number of adverse effects, most notably nephrotoxicity. This report describes a woman about to undergo liver transplantation in whom intravenous administration of cyclosporine was associated with an apparent anaphylactic reaction resulting in cardiopulmonary arrest. Similar reactions have thus far not been reported after oral administration of cyclosporine. Intravenous cyclosporine must be administered under close supervision and should be avoided in any patients with a history of prior allergic reactions to the drug or to a component of its intravenous formulation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3970058     DOI: 10.1016/0002-9343(85)90447-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

Review 1.  Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).

Authors:  L K Golightly; S S Smolinske; M L Bennett; E W Sutherland; B H Rumack
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

2.  Engineering polysaccharide-based polymeric micelles to enhance permeability of cyclosporin A across Caco-2 cells.

Authors:  Mira F Francis; Mariana Cristea; Yali Yang; Françoise M Winnik
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

3.  Pharmacokinetic interaction between cyclosporin and diltiazem.

Authors:  J Brockmöller; H H Neumayer; K Wagner; W Weber; G Heinemeyer; H Kewitz; I Roots
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

5.  Liposomal formulation eliminates acute toxicity and pump incompatibility of parenteral cyclosporine.

Authors:  S A Gruber; S Venkataram; D M Canafax; R J Cipolle; L Bowers; D Elsberry; M McGuiggan; P E Hynes; J A Ritz; F H Gould
Journal:  Pharm Res       Date:  1989-07       Impact factor: 4.200

6.  Cyclosporin A ameliorates cerebral oxidative metabolism and infarct size in the endothelin-1 rat model of transient cerebral ischaemia.

Authors:  Axel Forsse; Troels Halfeld Nielsen; Kevin Heebøll Nygaard; Carl-Henrik Nordström; Jan Bert Gramsbergen; Frantz Rom Poulsen
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

7.  Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor ® EL.

Authors:  Karl Henrik Johannes Ehinger; Magnus Joakim Hansson; Fredrik Sjövall; Eskil Elmér
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.